Extraordinary immune cells may hold the key to managing HIV

December 04, 2008

People who manage to control HIV on their own are providing scientists with valuable information about how the immune system eliminates virus-infected cells. A new study, published in the December 4th issue of Immunity, a Cell Press publication, identifies specific characteristics of the immune cells that successfully destroy HIV-infected cells and may drive strategies for developing the next generation of HIV vaccines and therapies.

Long-term nonprogressors (LTNPs) or elite controllers are rare individuals who are able to contain HIV for many years without any type of antiretroviral therapy. "Direct and indirect lines of evidence in humans and animal models suggest that virus-specific immune cells, called CD8+ T cells, mediate this control. However, the mechanisms by which this occurs remain unknown," says senior study author Dr. Mark Connors from the National Institute of Allergy and Infectious Disease in Bethesda, Maryland.

Using sophisticated new tools that can precisely measure the killing capacity of HIV-specific CD8+ T cells on a per-cell basis, Dr. Connors and colleagues compared how cells from LTNPs and progressors battle HIV by destroying infected cells. The CD8+ T cells of LTNPs efficiently eliminated infected cells by successfully loading granules with the proteins necessary for poking holes in the membranes of target cells and subsequently delivering a death-inducing molecule called granzyme B to cells infected with HIV.

In contrast, the CD8+ T cells of progressors lysed HIV-infected cells poorly. The researchers went on to show that CD8+ T cells of progressors were deficient in their ability to load lytic granules and deliver cytotoxic proteins to target cells. Elimination of infected cells readily distinguished LTNPs from progressors and was not restored in patients on antiretroviral therapy. However, the diminished abilities of the HIV-specific CD8+ T cells of progressors were reversible after treatment with phorbol ester and calcium ionophore, suggesting that these cells may retain the capacity to perform at the level seen in LTNPs.

Taken together, these findings demonstrate that LTNPs exhibit a superior ability to kill HIV-infected cells. "This capacity of CD8+ T cells is the function that is the best correlate of immunologic control we have observed thus far," says Dr. Stephen Migueles, the lead author of the study. He went on to say, "It will be very important for us to determine whether this is also predictive of immunologic control in vaccines. Clear correlates of immunologic control of HIV in chronic infection or vaccines have been sought for many years. If this function is also predictive of control in vaccines, this could be an extremely important milestone for HIV vaccine research."
-end-
The researchers include Stephen A. Migueles, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Christine M. Osborne, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD Cassandra Royce, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Alex A. Compton, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Rohan P. Joshi, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Kristin A. Weeks, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Julia E. Rood, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Amy M. Berkley, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Jonah B. Sacha, University of Wisconsin, Madison, WI; Nancy A. Cogliano-Shutta, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Margaret Lloyd, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Gregg Roby, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Richard Kwan, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Mary McLaughlin, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Sara Stallings, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Catherine Rehm, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Marie A. O'Shea, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; JoAnn Mican, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Beverly Z. Packard, OncoImmunin, Gaithersburg, MD; Akira Komoriya, OncoImmunin, Gaithersburg, MD; Sarah Palmer, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD; Ann P. Wiegand, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD; Frank Maldarelli, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD; John M. Coffin, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD; John W. Mellors, Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA; Claire W. Hallahan, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Dean A. Follman, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; and Mark Connors, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Cell Press

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.